Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 35Carcinoma, Neuroendocrine 10Carcinoid Tumor 10Neoplasms 6Adenoma, Islet Cell 6Carcinoma, Renal Cell 5Carcinoma, Islet Cell 5Somatostatinoma 4Pheochromocytoma 4Insulinoma 4Glucagonoma 4Carcinoma, Medullary 4Paraganglioma 3Neoplasm Metastasis 3Gastrinoma 3Carcinoma 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Neuroectodermal Tumors, Primitive 2Liver Neoplasms 2Head and Neck Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma, Follicular 2von Hippel-Lindau Disease 1Zollinger-Ellison Syndrome 1Tuberous Sclerosis 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Digestive System Neuroendocrine Tumor G1 × Everolimus × Endocrine × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡